Trial Profile
Repurposing Nucleoside Reverse Transcriptase Inhibitors for Treatment of AD
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 08 Jun 2023
Price :
$35
*
At a glance
- Drugs Emtricitabine (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Acronyms LINE-AD
- 05 Jun 2023 Planned End Date changed from 1 Aug 2023 to 31 Mar 2024.
- 05 Jun 2023 Planned primary completion date changed from 31 Mar 2023 to 31 Mar 2024.
- 21 Dec 2021 Status changed from not yet recruiting to recruiting.